Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | NEJM
The impact of immunotherapy in the treatment of solid tumors, What we found under 2021 Christmas tree
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Recent advances in gastrointestinal cancers
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study - ESMO Open
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577 - Marieke Pape, Pauline A.J. Vissers, Laurens V. Beerepoot, Mark I. van Berge Henegouwen, Sjoerd M. Lagarde, Stella
Milestones of PD-1 inhibition in gastric and esophageal cancer - memoinOncology
Practice Changing Immunotherapy Trials in Esophageal Cancer: Application in Clinical Practice
Selection and Sequencing of Treatment for Advanced Gastroesophageal Cancers
Immune Checkpoint Inhibitors for Esophageal Cancer
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junc
CheckMate 577 is the first trial to demonstrate the effectiveness of immunotherapy in the adjuvant setting for esophageal cancer or TEG - Onco Americas
CheckMate-577: Nivolumab Adjuvant Therapy in Patients with Resected Esophageal or GEJ Cancer Is Associated with Significant Disease-Free Survival - Journal of Oncology Navigation & Survivorship
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma - touchONCOLOGY
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial | Nature Communications
OPDIVO® (nivolumab) Efficacy Data for the Adjuvant Treatment of ESO and GEJ Cancers
ASCO 2021–Gastroesophageal tumor highlights | SpringerLink
Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review | JCO Oncology Practice
Frontiers | Prognostication and optimal criteria of circumferential margin involvement for esophageal cancer after chemoradiation and esophagectomy
(PDF) A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
